Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01441635
Other study ID # M12-663
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 8, 2011
Est. completion date May 17, 2014

Study information

Verified date July 2021
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this proof-of-concept study is to assess the safety and effectiveness of elagolix versus placebo to reduce uterine bleeding associated with uterine fibroids, and to reduce fibroid volume and uterine volume in premenopausal women 20 to 49 years of age with heavy uterine bleeding.


Recruitment information / eligibility

Status Completed
Enrollment 271
Est. completion date May 17, 2014
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 49 Years
Eligibility Inclusion Criteria: - Subject is a pre-menopausal female 20 to 49 years of age. - Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound assessed by a central reader and verification that a fibroid present met the following criteria: - At least 1 fibroid with diameter = 2 cm (longest diameter), or multiple small fibroids with a total uterine volume of = 200 cm³ to = 2,500 cm³ (approximately 22 weeks' gestation) as documented by a centrally read ultrasound. - Only intramural, submucosal non-pedunculated, and subserosal fibroids qualified subjects for enrollment (intracavitary pedunculated fibroids were exclusionary). - Ultrasound procedures were performed during the Screening Period, and subjects were not randomized until the investigator reviewed the central reader results verifying the inclusion requirements. - Subject has a history of regular menstrual cycles between 24 to 35 days. - Subject has heavy uterine bleeding associated with uterine fibroids as evidenced by blood loss > 80 mL during 2 screening menstrual cycles, measured by the alkaline hematin method. Exclusion Criteria: - Subject has had a myomectomy, uterine artery embolization, or high intensity focused ultrasound for fibroid destruction within 1 year prior to randomization or any history of endometrial ablation. - Subject has a history of osteoporosis or other metabolic bone disease. - Subject shows evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including depression), or neurologic diseases or any uncontrolled medical illness such as uncontrolled type 2 diabetes. - Subject has a history of clinically significant condition(s) including but not limited to: - Endometriosis - Epilepsy or seizures - Type 1 diabetes - Any cancer (except basal cell carcinoma of the skin), including breast or ovarian cancer or subject has taken any systemic cancer chemotherapy

Study Design


Intervention

Drug:
Elagolix
Elagolix tablets
Placebo
Matching placebo tablets
Estradiol/Norethindrone acetate (E2/NETA)
A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
Estradiol
1.0 mg micronized estradiol tablets administered once a day
Progesterone
Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
AbbVie (prior sponsor, Abbott)

References & Publications (1)

Archer DF, Stewart EA, Jain RI, Feldman RA, Lukes AS, North JD, Soliman AM, Gao J, Ng JW, Chwalisz K. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017 Jul;108(1):152-160.e4. doi: 10.1016/j.fertnstert.2017.05.006. Epub 2017 Jun 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL) The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.
Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)
Secondary Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL) The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.
Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)
Secondary Percentage of Participants With MBL < 80 mL and With a = 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.
Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)
Secondary Percentage of Participants With MBL < 80 mL During the Last 28 Days of Treatment The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.
The last 28 days of treatment (approximately days 61 to 90)
Secondary Percentage of Participants With a = 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.
Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)
Secondary Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3 The percentage of subjects with changes in hemoglobin concentration from Baseline to Month 3 in each of the following categories:
No change from baseline in hemoglobin
Decrease from baseline in hemoglobin = -0.5 g/dL
Decrease from baseline in hemoglobin = -1.0 g/dL
Increase from baseline in hemoglobin = 0.5 g/dL
Increase from baseline in hemoglobin = 1.0 g/dL
The above categories are not all mutually exclusive or exhaustive.
Baseline and Month 3
Secondary Change in Hemoglobin Concentration From Baseline to Month 3 Baseline and Month 3
Secondary Change From Baseline to Month 3 in Uterine Bleeding Score Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)
Secondary Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with any uterine bleeding is defined as a days with a bleeding score = 1.
Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)
Secondary Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with moderate to very heavy bleeding is defined as a days with a bleeding score = 3.
Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)
Secondary Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3 Participants recorded the previous days' presence and severity of bleeding every morning in an eDiary according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
Any bleeding is defined as a score = 1 and moderate to very heavy bleeding is defined as a score = 3.
Month 3 (average bleeding score over days 61 to 90)
Secondary Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment Suppression of bleeding is defined as no record of bleeding (spotting allowed) in the e-diary and no record of bleeding Indicated in the alkaline hematin data during the last 56 days of treatment.
Amenorrhea is defined as no record of bleeding or spotting indicated in the e-diary and no record of bleeding or spotting Indicated in the alkaline hematin data during the last 56 days of treatment.
The last 56 days of treatment (approximately days 33 to 90)
Secondary Percent Change From Baseline to Month 3 in Uterine Volume Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. Baseline and month 3
Secondary Percentage of Participants With = 25% Reduction in Uterine Volume at Month 3 / Final Visit Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.
Secondary Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. Baseline and month 3
Secondary Percentage of Participants With = 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center. Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.
Secondary Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL) The UFS-QoL is a disease-specific, self-administered, validated questionnaire developed to evaluate the symptoms associated with uterine fibroids and their impact on health-related quality of life (HRQL) in women with symptomatic uterine fibroids. The questionnaire consists of 37 questions, divided into 2 parts: 1) an 8-item symptom severity scale and 2) a 29-item HRQL subscale comprising 6 domains (concern, activities, energy/mood, control, self-consiousness, and sexual function), with a 4-week recall. All items are scored on a 5-point scale, ranging from "not at all" to "a very great deal" for symptom severity items and "none of the time" to "all of the time" for the HRQL items. Symptom severity and HRQL subscale scores were summed and transformed into a 0 to 100 point scale to provide a total score for each of the 2 components.
Lower symptom severity scores indicate better quality of life and higher total HRQL scores indicate better quality of life.
Baseline and month 3
Secondary Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores The uterine fibroid daily symptom scale is self-administered questionnaire, with a scale that ranges from 0 to 10 for the symptoms of pelvic pain, fatigue, and cramping and the impact of uterine fibroids on the subject's daily life, with 0 being the absence of the symptom and 10 being the worst severity of the symptoms or completely preventing the subjects from performing daily activities. Participants self-reported values daily in the e-Diary. Baseline (average score over the 30 days prior to first dose) and month 3 (average score over days 61 to 90)
Secondary Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0 The Subject Intention Questionnaire (SSIQ) is a non-validated, exploratory questionnaires intended to evaluate the subject's intent to undergo surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to consider surgery) to 10 (very likely to consider surgery).
SSIQ included the 2 following questions:
How likely are you to consider having myomectomy surgery to treat your uterine fibroid if your symptoms continue as they are now?
How likely are you to consider hysterectomy surgery if your uterine fibroid symptoms continue as they are now?
Baseline and month 3
Secondary Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0 The Physician Intention Questionnaire (PSIQ) is a non-validated, exploratory questionnaire intended to evaluate the investigator's intent to recommend surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to recommend surgery) to 10 (very likely to recommend surgery).
The PSIQ included the 2 following questions:
How likely are you to recommend myomectomy to treat this patient's uterine fibroid if her symptoms continue as they are now?
How likely are you to recommend definitive surgery hysterectomy for this patient if her uterine fibroid symptoms continue as they are now?
Baseline and month 3
See also
  Status Clinical Trial Phase
Completed NCT00958334 - Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 Phase 2
Withdrawn NCT04567589 - A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
Recruiting NCT05078307 - Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids N/A
Recruiting NCT02283502 - Clinical Test of the MRgHIFU System on Uterine Fibroids Phase 1
Completed NCT01739621 - Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 Phase 2
Completed NCT01631903 - Extension of Study ZPV-200 Phase 2
Withdrawn NCT00768742 - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study N/A
Completed NCT00152256 - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids Phase 3
Not yet recruiting NCT03586947 - Association Between Vitamin D and the Risk of Uterine Fibroids N/A
Completed NCT02925494 - An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Not yet recruiting NCT06055114 - Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
Terminated NCT05026502 - A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
Withdrawn NCT04567095 - A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
Withdrawn NCT03699176 - Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Phase 3
Not yet recruiting NCT02884960 - Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization N/A
Completed NCT02472184 - Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy N/A
Completed NCT01452659 - Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids Phase 2
Terminated NCT01555073 - Preemptive Analgesia Following Uterine Artery Embolization Phase 4
Completed NCT01229826 - Magnetic Resonance Elastography (MRE) of Uterine Fibroids N/A
Terminated NCT00785356 - Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids Phase 3